Anti-pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: A plausible mode of action in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3853-3860

  Uccelletti, Daniela ^a   Zanni, Elena ^a   Marcellini, Ludovica ^b   Palleschi, Claudio ^a   Barra, Donatella ^b   Mangoni, Maria Luisa ^b  

^a Pasteur Institute   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; H2N GLYCYLISOLEUCYLPHENYLALANYLSERYLLYSYLLEUCYLALANYLGLYCYLLYSYLLYSYLISOLEUCYLLYSYLASPARAGINYLLEUCYLLEUCYLISOLEUCYLSERYLGLYCYLLEUCYLLYSYLGLYCINE CONH2; H2N GLYCYLISOLEUCYLPHENYLALANYLSERYLLYSYLLEUCYLALANYLGLYCYLLYSYLLYSYLLEUCYLLYSYLASPARAGINYLLEUCYLLEUCYLISOLEUCYLSERYLGLYCINE CONH2; H2N LEUCYLLEUCYLPROLYLISOLEUCYLVALYLGLYCYLASPARAGINYLLEUCYLLEUCYLLYSYLSERYLLEUCYLLEUCINE CONH2; H2N PHENYLALANYLLEUCYLPROLYLLEUCYLISOLEUCYLGLYCYLLYSYLVALYLLEUCYLSERYLGLYCYLISOLEUCYLLEUCINE CONH2; H2N PHENYLALANYLVALYLGLUTAMINYLTRYPTOPHYLPHENYLALANYLSERYLLYSYLPHENYLALANYLLEUCYLGLYCYLARGINYLISOLEUCYLLEUCINE CONH2; MEROPENEM; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG MECHANISM; FROG; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE PERMEABILITY; MULTIDRUG RESISTANCE; NEMATODIASIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN;

AMPHIBIAN PROTEINS; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANURA; CAENORHABDITIS ELEGANS; CELLS, CULTURED; GLYCOSIDES; HEMOLYSIS; HUMANS; PREGNENOLONE; PROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SKIN;

EID: 77956099078     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00154-10     Document Type: Article

References (40)

1. Ausubel, F. M. 2005. Are innate immune signaling pathways in plants and animals conserved? Nat. Immunol. 6:973-979.
2. Bhavsar, A. P., and E. D. Brown. 2006. The worm turns for antimicrobial discovery. Nat. Biotechnol. 24:1098-1100.
3. Carotenuto, A., S. Malfi, M. R. Saviello, P. Campiglia, I. Gomez-Monterrey, M. L. Mangoni, L. M. Gaddi, E. Novellino, and P. Grieco. 2008. A different molecular mechanism underlying antimicrobial and hemolytic actions of temporins A and L. J. Med. Chem. 51:2354-2362.
4. Chamilos, G., M. S. Lionakis, R. E. Lewis, and D. P. Kontoyiannis. 2007. Role of mini-host models in the study of medically important fungi. Lancet Infect. Dis. 7:42-55.
5. Cirioni, O., C. Silvestri, R. Ghiselli, F. Orlando, A. Riva, F. Mocchegiani, L. Chiodi, S. Castelletti, E. Gabrielli, V. Saba, G. Scalise, and A. Giacometti. 2008. Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J. Antimicrob. Chemother. 62:1332-1338.
6. Conlon, J. M. 2008. Reflections on a systematic nomenclature for antimicrobial peptides from the skins of frogs of the family Ranidae. Peptides 29:1815-1819.
7. Dohar, J. E., P. A. Hebda, R. Veeh, M. Awad, J. W. Costerton, J. Hayes, and G. D. Ehrlich. 2005. Mucosal biofilm formation on middle-ear mucosa in a nonhuman primate model of chronic suppurative otitis media. Laryngoscope 115:1469-1472.
8. Garsin, D. A., C. D. Sifri, E. Mylonakis, X. Qin, K. V. Singh, B. E. Murray, S. B. Calderwood, and F. M. Ausubel. 2001. A simple model host for identifying Gram-positive virulence factors. Proc. Natl. Acad. Sci. U. S. A. 98: 10892-10897.
9. Gill, M. S., A. Olsen, J. N. Sampayo, and G. J. Lithgow. 2003. An automated high-throughput assay for survival of the nematode Caenorhabditis elegans. Free Radic. Biol. Med. 35:558-565.
10. Gooderham, W. J., M. Bains, J. B. McPhee, I. Wiegand, and R. E. Hancock. 2008. Induction by cationic antimicrobial peptides and involvement in intrinsic polymyxin and antimicrobial peptide resistance, biofilm formation, and swarming motility of PsrA in Pseudomonas aeruginosa. J. Bacteriol. 190:5624-5634.
11. Hancock, R. E. 1997. Peptide antibiotics. Lancet 349:418-422.
12. Hancock, R. E., and D. P. Speert. 2000. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist. Updat. 3:247-255.
13. Hassett, D. J., J. Cuppoletti, B. Trapnell, S. V. Lymar, J. J. Rowe, S. S. Yoon, G. M. Hilliard, K. Parvatiyar, M. C. Kamani, D. J. Wozniak, S. H. Hwang, T. R. McDermott, and U. A. Ochsner. 2002. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv. Drug Deliv. Rev. 54:1425-1443.
14. Huang, L. C., R. L. Redfern, S. Narayanan, R. Y. Reins, and A. M. Mc-Dermott. 2007. In vitro activity of human beta-defensin 2 against Pseudomonas aeruginosa in the presence of tear fluid. Antimicrob. Agents Chemother. 51:3853-3860.
15. Irazoqui, J. E., J. M. Urbach, and F. M. Ausubel. 2010. Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates. Nat. Rev. Immunol. 10:47-58.
16. Islas-Rodrìguez, A. E., L. Marcellini, B. Orioni, D. Barra, L. Stella, and M. L. Mangoni. 2009. Esculentin 1-21: a linear antimicrobial peptide from frog skin with inhibitory effect on bovine mastitis-causing bacteria. J. Pept. Sci. 15:607-614.
17. Jenssen, H., P. Hamill, and R. E. Hancock. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511.
18. Kampkötter, A., T. Pielarski, R. Rohrig, C. Timpel, Y. Chovolou, W. Watjen, and R. Kahl. 2007. The ginkgo biloba extract EGb761 reduces stress sensitivity, ROS accumulation and expression of catalase and glutathione S-transferase 4 in Caenorhabditis elegans. Pharmacol. Res. 55: 139-147. (Pubitemid 46186041)
19. Kaul, D. R., C. D. Collins, and R. C. Hyzy. 2008. New developments in antimicrobial use in sepsis. Curr. Pharm. Des. 14:1912-1920.
20. Kim, D. H., and F. M. Ausubel. 2005. Evolutionary perspectives on innate immunity from the study of Caenorhabditis elegans. Curr. Opin. Immunol. 17:4-10.
21. Li, X. Z., K. Poole, and H. Nikaido. 2003. Contributions of MexAB-OprM and an EmrE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob. Agents Chemother. 47:27-33.
22. Maisetta, G., G. Batoni, S. Esin, W. Florio, D. Bottai, F. Favilli, and M. Campa. 2006. In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob. Agents Chemother. 50: 806-809.
23. Mangoni, M. L. 2006. Temporins, anti-infective peptides with expanding properties. Cell. Mol. Life Sci. 63:1060-1069.
24. Mangoni, M. L., D. Fiocco, G. Mignogna, D. Barra, and M. Simmaco. 2003. Functional characterisation of the 1-18 fragment of esculentin-1b, an antimicrobial peptide from Rana esculenta. Peptides 24:1771-1777.
25. Mangoni, M. L., N. Grovale, A. Giorgi, G. Mignogna, M. Simmaco, and D. Barra. 2000. Structure-function relationships in bombinins H, antimicrobial peptides from Bombina skin secretions. Peptides 21:1673-1679.
26. Mangoni, M. L., G. Maisetta, M. Di Luca, L. M. Gaddi, S. Esin, W. Florio, F. L. Brancatisano, D. Barra, M. Campa, and G. Batoni. 2008. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains. Antimicrob. Agents Chemother. 52:85-91.
27. Marcellini, L., M. Borro, G. Gentile, A. C. Rinaldi, L. Stella, P. Aimola, D. Barra, and M. L. Mangoni. 2009. Esculentin-1b(1-18) - a membrane-active antimicrobial peptide that synergizes with antibiotics and modifies the expression level of a limited number of proteins in Escherichia coli. FEBS J. 276:5647-5664.
28. Montie, T. C., D. Doyle-Huntzinger, R. C. Craven, and I. A. Holder. 1982. Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model. Infect. Immun. 38:1296-1298.
29. Mookherjee, N., and R. E. Hancock. 2007. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 64:922-933.
30. Moy, T. I., A. R. Ball, Z. Anklesaria, G. Casadei, K. Lewis, and F. M. Ausubel. 2006. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. U. S. A. 103:10414-10419.
31. Mylonakis, E., and A. Aballay. 2005. Worms and flies as genetically tractable animal models to study host-pathogen interactions. Infect. Immun. 73:3833-3841.
32. Navon-Venezia, S., R. Feder, L. Gaidukov, Y. Carmeli, and A. Mor. 2002. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 46:689-694.
33. Rinaldi, A. C., M. L. Mangoni, A. Rufo, C. Luzi, D. Barra, H. Zhao, P. K. Kinnunen, A. Bozzi, A. Di Giulio, and M. Simmaco. 2002. Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. Biochem. J. 368:91-100.
34. Rowe, S. M., S. Miller, and E. J. Sorscher. 2005. Cystic fibrosis. N. Engl. J. Med. 352:1992-2001.
35. Shai, Y. 2002. Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248.
36. Shapira, M., B. J. Hamlin, J. Rong, K. Chen, M. Ronen, and M. W. Tan. 2006. A conserved role for a GATA transcription factor in regulating epithelial innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 103:14086-14091.
37. Sifri, C. D., J. Begun, and F. M. Ausubel. 2005. The worm has turned - microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol. 13:119-127.
38. Sifri, C. D., J. Begun, F. M. Ausubel, and S. B. Calderwood. 2003. Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infect. Immun. 71:2208-2217.
39. Stiernagel, T. 11 February 2006, posting date. Maintenance of C. elegans, WormBook, ed. The C. elegans Research Community, WormBook. doi/ 10.1895/wormbook.1.101.1. http://www.wormbook.org.
40. Zhang, L., and T. J. Falla. 2009. Host defense peptides for use as potential therapeutics. Curr. Opin. Invest. Drugs 10:164-171.